Please enable JavaScript to continue using this application.

Compare $ATRA vs $CRDF | Chartloom

Compare

$ATRA vs $CRDF

Atara Biotherapeutics Inc · Cardiff Oncology Inc

ATRA

Atara Biotherapeutics Inc

CRDF

Cardiff Oncology Inc

Compare $ATRA vs $CRDF

Comparing Atara Biotherapeutics Inc and Cardiff Oncology Inc

ATRAAtara Biotherapeutics Inc

CRDFCardiff Oncology Inc

ATRAAtara Biotherapeutics Inc

Market cap

$85M

P/E (TTM)

—

Forward P/E (NTM)

14.78x

Forward P/S (NTM)

2.47x

Rev growth (TTM)

-96.7%

YTD performance

-46.7%

52W performance

-40.2%

FCF yield

-25.6%

CRDFCardiff Oncology Inc

Market cap

$84M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

244.08x

Rev growth (TTM)

-7.0%

YTD performance

-59.4%

52W performance

-54.6%

FCF yield

-48.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ATRA

CRDF

Detailed metrics comparison

ATRA

Atara Biotherapeutics Inc

CRDF

Cardiff Oncology Inc

Market Cap

ATRA$85M

CRDF$84M

Enterprise Value

ATRA$124M

CRDF$75M

Price

ATRA$9.48

CRDF$1.08

P/E Ratio

ATRAN/A

CRDFN/A

P/S Ratio

ATRA13.79x

CRDF165.40x

EV/Sales

ATRA19.98x

CRDF147.30x

EV/EBITDA

ATRA3.51x

CRDF0.00x

P/B Ratio

ATRA12.86x

CRDF3.28x

P/FCF Ratio

ATRAN/A

CRDFN/A

EV/FCF

ATRA-5.65x

CRDF-1.83x

PEG Ratio

ATRAN/A

CRDFN/A

Forward P/E (NTM)

ATRA14.78x

CRDFN/A

Forward P/S (NTM)

ATRA2.47x

CRDF244.08x

Revenue (TTM)

ATRA$6M

CRDF$508K

Revenue Growth (YoY)

ATRA-96.7%

CRDF-7.0%

Forward Rev Growth

ATRA1983.2%

CRDF-19.6%

Gross Margin (TTM)

ATRA91.4%

CRDF100.0%

Operating Margin (TTM)

ATRA0.0%

CRDF0.0%

EBITDA Margin (TTM)

ATRA-194.7%

CRDF-8251.0%

Net Margin (TTM)

ATRA-269.4%

CRDF-7889.0%

FCF Margin (TTM)

ATRA-353.5%

CRDF-8054.3%

Net Income (TTM)

ATRA$-17M

CRDF$-40M

FCF (TTM)

ATRA$-22M

CRDF$-41M

EPS (TTM)

ATRA-$1.11

CRDF-$0.59

ROE (TTM)

ATRA-31542.0%

CRDF-10308.0%

ROA (TTM)

ATRA-7301.0%

CRDF-7551.0%

ROIC (TTM)

ATRA-30684.0%

CRDF-10308.0%

Cash

ATRA$3M

CRDF$9M

Debt

ATRA$42M

CRDF$0

Net Cash/Debt

ATRA$-38M

CRDF$9M

Current Ratio (TTM)

ATRA1.98x

CRDF3.30x

Quick Ratio (TTM)

ATRA1.98x

CRDF3.21x

Debt/Equity (TTM)

ATRA0.12x

CRDF0.00x

Debt/Assets (TTM)

ATRA0.0%

CRDF0.0%

Interest Coverage (TTM)

ATRAN/A

CRDFN/A

Net Debt/EBITDA (TTM)

ATRA0.00x

CRDF0.00x

Beta

ATRA0.31

CRDF1.49

52W Performance

ATRA-40.2%

CRDF-54.6%

YTD Performance

ATRA-46.7%

CRDF-59.4%

% from 52W High

ATRA-50.5%

CRDF-67.4%

% from 52W Low

ATRA141.8%

CRDF42.7%

Asset Turnover (TTM)

ATRA0.27x

CRDF0.01x

FCF Yield (TTM)

ATRA-25.6%

CRDF-48.7%

Earnings Yield (TTM)

ATRA-19.5%

CRDF-47.7%

Dividend Yield (TTM)

ATRAN/A

CRDFN/A

Rule of 40

ATRA-450.2

CRDF-8,061.3

EV/GP/RG

ATRA0.05

CRDFN/A

Ticker research

View ATRA research View CRDF research

Metric	ATRA Atara Biotherapeutics Inc	CRDF Cardiff Oncology Inc
Market & Valuation
Market Cap	$85M	$84M
Enterprise Value	$124M	$75M
Price	$9.48	$1.08
P/E Ratio	N/A	N/A
P/S Ratio	13.79x	165.40x
EV/Sales	19.98x	147.30x
EV/EBITDA	3.51x	0.00x
P/B Ratio	12.86x	3.28x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.65x	-1.83x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	14.78x	N/A
Forward P/S (NTM)	2.47x	244.08x
Revenue & Growth
Revenue (TTM)	$6M	$508K
Revenue Growth (YoY)	-96.7%	-7.0%
Forward Rev Growth	1983.2%	-19.6%
Profitability
Gross Margin (TTM)	91.4%	100.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-194.7%	-8251.0%
Net Margin (TTM)	-269.4%	-7889.0%
FCF Margin (TTM)	-353.5%	-8054.3%
Net Income (TTM)	$-17M	$-40M
FCF (TTM)	$-22M	$-41M
EPS (TTM)	-$1.11	-$0.59
ROE (TTM)	-31542.0%	-10308.0%
ROA (TTM)	-7301.0%	-7551.0%
ROIC (TTM)	-30684.0%	-10308.0%
Financial Health
Cash	$3M	$9M
Debt	$42M	$0
Net Cash/Debt	$-38M	$9M
Current Ratio (TTM)	1.98x	3.30x
Quick Ratio (TTM)	1.98x	3.21x
Debt/Equity (TTM)	0.12x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.31	1.49
52W Performance	-40.2%	-54.6%
YTD Performance	-46.7%	-59.4%
% from 52W High	-50.5%	-67.4%
% from 52W Low	141.8%	42.7%
Efficiency & Yields
Asset Turnover (TTM)	0.27x	0.01x
FCF Yield (TTM)	-25.6%	-48.7%
Earnings Yield (TTM)	-19.5%	-47.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-450.2	-8,061.3
EV/GP/RG	0.05	N/A
Ticker research	View ATRA research	View CRDF research

Valuation

P/S Ratio

ATRA

13.79x

CRDF

165.40x

EV/FCF

ATRA

-5.65x

CRDF

-1.83x

Growth & revenue

Revenue Growth TTM

CRDF

-7.0%

ATRA

-96.7%

Forward Revenue Growth

ATRA

1983.2%

CRDF

-19.6%

Profitability & performance

Gross Margin

CRDF

100.0%

ATRA

91.4%

ROE

CRDF

-10308.0%

ATRA

-31542.0%

FCF Yield %

ATRA

-25.6%

CRDF

-48.7%

52-Week Performance

ATRA

-40.2%

CRDF

-54.6%

Detailed metrics comparison

ATRA

Atara Biotherapeutics Inc

CRDF

Cardiff Oncology Inc

Market Cap

ATRA$85M

CRDF$84M

Enterprise Value

ATRA$124M

CRDF$75M

Price

ATRA$9.48

CRDF$1.08

P/E Ratio

ATRAN/A

CRDFN/A

P/S Ratio

ATRA13.79x

CRDF165.40x

EV/Sales

ATRA19.98x

CRDF147.30x

EV/EBITDA

ATRA3.51x

CRDF0.00x

P/B Ratio

ATRA12.86x

CRDF3.28x

P/FCF Ratio

ATRAN/A

CRDFN/A

EV/FCF

ATRA-5.65x

CRDF-1.83x

PEG Ratio

ATRAN/A

CRDFN/A

Forward P/E (NTM)

ATRA14.78x

CRDFN/A

Forward P/S (NTM)

ATRA2.47x

CRDF244.08x

Revenue (TTM)

ATRA$6M

CRDF$508K

Revenue Growth (YoY)

ATRA-96.7%

CRDF-7.0%

Forward Rev Growth

ATRA1983.2%

CRDF-19.6%

Gross Margin (TTM)

ATRA91.4%

CRDF100.0%

Operating Margin (TTM)

ATRA0.0%

CRDF0.0%

EBITDA Margin (TTM)

ATRA-194.7%

CRDF-8251.0%

Net Margin (TTM)

ATRA-269.4%

CRDF-7889.0%

FCF Margin (TTM)

ATRA-353.5%

CRDF-8054.3%

Net Income (TTM)

ATRA$-17M

CRDF$-40M

FCF (TTM)

ATRA$-22M

CRDF$-41M

EPS (TTM)

ATRA-$1.11

CRDF-$0.59

ROE (TTM)

ATRA-31542.0%

CRDF-10308.0%

ROA (TTM)

ATRA-7301.0%

CRDF-7551.0%

ROIC (TTM)

ATRA-30684.0%

CRDF-10308.0%

Cash

ATRA$3M

CRDF$9M

Debt

ATRA$42M

CRDF$0

Net Cash/Debt

ATRA$-38M

CRDF$9M

Current Ratio (TTM)

ATRA1.98x

CRDF3.30x

Quick Ratio (TTM)

ATRA1.98x

CRDF3.21x

Debt/Equity (TTM)

ATRA0.12x

CRDF0.00x

Debt/Assets (TTM)

ATRA0.0%

CRDF0.0%

Interest Coverage (TTM)

ATRAN/A

CRDFN/A

Net Debt/EBITDA (TTM)

ATRA0.00x

CRDF0.00x

Beta

ATRA0.31

CRDF1.49

52W Performance

ATRA-40.2%

CRDF-54.6%

YTD Performance

ATRA-46.7%

CRDF-59.4%

% from 52W High

ATRA-50.5%

CRDF-67.4%

% from 52W Low

ATRA141.8%

CRDF42.7%

Asset Turnover (TTM)

ATRA0.27x

CRDF0.01x

FCF Yield (TTM)

ATRA-25.6%

CRDF-48.7%

Earnings Yield (TTM)

ATRA-19.5%

CRDF-47.7%

Dividend Yield (TTM)

ATRAN/A

CRDFN/A

Rule of 40

ATRA-450.2

CRDF-8,061.3

EV/GP/RG

ATRA0.05

CRDFN/A

Ticker research

View ATRA research View CRDF research

Metric	ATRA Atara Biotherapeutics Inc	CRDF Cardiff Oncology Inc
Market & Valuation
Market Cap	$85M	$84M
Enterprise Value	$124M	$75M
Price	$9.48	$1.08
P/E Ratio	N/A	N/A
P/S Ratio	13.79x	165.40x
EV/Sales	19.98x	147.30x
EV/EBITDA	3.51x	0.00x
P/B Ratio	12.86x	3.28x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.65x	-1.83x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	14.78x	N/A
Forward P/S (NTM)	2.47x	244.08x
Revenue & Growth
Revenue (TTM)	$6M	$508K
Revenue Growth (YoY)	-96.7%	-7.0%
Forward Rev Growth	1983.2%	-19.6%
Profitability
Gross Margin (TTM)	91.4%	100.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-194.7%	-8251.0%
Net Margin (TTM)	-269.4%	-7889.0%
FCF Margin (TTM)	-353.5%	-8054.3%
Net Income (TTM)	$-17M	$-40M
FCF (TTM)	$-22M	$-41M
EPS (TTM)	-$1.11	-$0.59
ROE (TTM)	-31542.0%	-10308.0%
ROA (TTM)	-7301.0%	-7551.0%
ROIC (TTM)	-30684.0%	-10308.0%
Financial Health
Cash	$3M	$9M
Debt	$42M	$0
Net Cash/Debt	$-38M	$9M
Current Ratio (TTM)	1.98x	3.30x
Quick Ratio (TTM)	1.98x	3.21x
Debt/Equity (TTM)	0.12x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.31	1.49
52W Performance	-40.2%	-54.6%
YTD Performance	-46.7%	-59.4%
% from 52W High	-50.5%	-67.4%
% from 52W Low	141.8%	42.7%
Efficiency & Yields
Asset Turnover (TTM)	0.27x	0.01x
FCF Yield (TTM)	-25.6%	-48.7%
Earnings Yield (TTM)	-19.5%	-47.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-450.2	-8,061.3
EV/GP/RG	0.05	N/A
Ticker research	View ATRA research	View CRDF research